|Day Low/High||3.00 / 3.16|
|52 Wk Low/High||1.46 / 8.05|
New Preclinical Data to be Presented on First-of-Kind Product Candidates Derived from Master Engineered Pluripotent Cell Lines
Some small names are interesting, but more-aggressive position trades are not developing right now.
Insiders have an edge in this complex sector, so it's worth checking them out.
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.
Traders are also looking for smaller-caps that can move big around the holiday.
Five Additional Presentations to Highlight the Company's Cellular Immunotherapy Programs